Nucleotide DNA polymerase inhibitor MIV-818 for liver cancer, awarded orphan drug title by the European Union
-
Last Update: 2020-07-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Medivir AB announced that the European Commission, in accordance with the advice of the European Agency for drugManagement(EMA), has granted orphan drug products the designation of MIV-818 for the most common primary hepatic cell carcinoma (HCC) patientsOrphan drug products designated as drug companies provide certain regulatory and financial incentives for all diseases involved in less than five out of every 10,000 people in the EUThe name provides a variety of incentives, including agreement assistance, EU centralized licensing procedures and reduced regulatory costs, as well as the potential for 10 years of market dominance in the EUliver cell cancerliver cancer is the fifth most common cancer in the world, but is a rare disease in Europe and the United StatesDespite the treatment, the benefits of treatment for advanced liver cancer are low and the mortality rate remains highHCC is a very diverse disease with a variety of cancer cell types and no tumor-specific mutations, resulting in a lack ofmoleculartarget targetingdrugsLimited overall benefits for patients, coupled with poor prognosis for patients with advanced and middle-stage liver cancer, resulted in unmet medical needsmIV-818MIV-818 is a nucleotide DNA polymerase inhibitor, previously in the form of a drug designed to selectively treat liver cancer cells and minimize side effectsThe drug has the potential to become the first liver-targeted oral drug in patients with liver cancer
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
